AXGNHealthcare · Medical Devices

AXGN Stock Forecast: AxoGen, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026

$36

−2.44% on the day

The 10 Wall Street analysts covering AxoGen, Inc. hold a median 12-month price target of $54 — +48.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 6 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap

$2.2B

Ticker Nerd rank

81 / 100

Median analyst target

$54

Analysts covering

Revenue$69.7M+23.1% y/y

Operating income−$2.2M

Net income−$1.5M

Free cash flow$5.5M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−14.4%

−24.8%

YTD

+10.9%

+111.6%

From 52W high

−29.8%

From 52W low

+132.9%

$16

$52

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

AXGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AxoGen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026

81 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum

Quality

Issuance

Volatility

Accruals

Revisions

Value

Growth

Size

Momentum (95): The shares have been drifting up relative to others.

Growth (51): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (34): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AXGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AXGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts

10 Buy0 Hold0 Sell

Low $48Median $54High $58

The green dot is the last close — the median target sits +48.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 1 moved it down.

Date	Firm	Action	Rating	Target
1 Oct 2026	Truist Securities	Maintains	Buy	$60 → $53
25 Sept 2026	Raymond James	Maintains	Outperform	$48 → $53
26 Aug 2026	Truist Securities	Initiates	Buy	$60
26 Aug 2026	Truist Securities	Initiates	Buy	—
30 July 2026	Canaccord Genuity	Maintains	Buy	—
30 July 2026	Canaccord Genuity	Maintains	Buy	$50 → $55
30 July 2026	Citizens	Maintains	Market Outperform	$50 → $55
30 July 2026	Citizens	Maintains	Market Outperform	—
30 July 2026	HC Wainwright & Co.	Maintains	Buy	—
30 July 2026	HC Wainwright & Co.	Maintains	Buy	$50 → $53
29 Apr 2026	Canaccord Genuity	Maintains	Buy	$45 → $50
29 Apr 2026	Canaccord Genuity	Maintains	Buy	—
29 Apr 2026	Citizens	Maintains	Market Outperform	$42 → $50
29 Apr 2026	Citizens	Maintains	Market Outperform	—
29 Apr 2026	HC Wainwright & Co.	Maintains	Buy	$39 → $50
29 Apr 2026	HC Wainwright & Co.	Maintains	Buy	—
29 Apr 2026	Wells Fargo	Maintains	Overweight	—
29 Apr 2026	Wells Fargo	Maintains	Overweight	$40 → $48
23 Apr 2026	Lake Street	Maintains	Buy	$40 → $50
23 Apr 2026	Lake Street	Maintains	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AXGN appears on the weeks it earns a place.

Performance

AXGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, AxoGen, Inc. returned +111.6% against +17.3% for the S&P 500, dividends included.

AXGN vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AXGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

EPS revision, 90 days

−6.1%

Analysts raising

Analysts cutting

Fundamentals

AxoGen, Inc. (AXGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −110.0×
Price / sales: 8.7×
Price / book: 7.8×
EV / EBITDA: −321.5×

Growth & margins

Revenue growth (YoY): 23.1%
Earnings growth (YoY): 23.1%
Gross margin: 72.7%
Operating margin: −3.1%
Net margin: −13.4%

Returns & dividend

Return on equity: −18.2%
Return on assets: −3.1%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

AxoGen, Inc. (AXGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

AxoGen, Inc. has a market value of $2.2B and an enterprise value of $1.9B.
Revenue in the twelve months to 30 June 2026: $251.2M. The latest quarter grew 23.1% year on year.
Net income over the same four quarters: −$33.5M, a −13.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.68.
Free cash flow in the twelve months to 30 June 2026: $6.5M.
Shares outstanding: 53.2M.
Trailing P/E: −110.0×; forward P/E: 54.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
AxoGen, Inc. employs 622 people — $404K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

AXGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
AXGNAxoGen, Inc.	$2.2B	81
ALMRAlamar Biosciences, Inc. (California)	$2.2B	4
INSPInspire Medical Systems, Inc.	$1.9B	83
UFPTUFP Technologies, Inc.	$2.3B	80
BFLYButterfly Network, Inc.	$2.4B	73
ESTAEstablishment Labs Holdings, Inc.	$1.9B	70
NVCRNovoCure Ltd.	$1.7B	96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AxoGen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AXGN news & analysis

Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)

Zacks Investment Research · 5 Oct 2026positive

AxoGen (AXGN) has declined 22.6% over the past four weeks and is now technically in oversold territory. According to the report, strong agreement among Wall Street analysts in revising earnings estimates higher indicates the stock may be poised for a trend reversal.

Why it matters — For AxoGen watchers, this report suggests that the recent selloff may have run its course, with analyst estimate revisions pointing to a possible turnaround in the stock's direction.

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

GlobeNewsWire · 1 Oct 2026positive

Axogen announced the completion of its acquisition of BioCircuit Technologies, adding NerveTape, the first FDA-cleared device for sutureless peripheral nerve repair, to its portfolio. The announcement was made from Alachua, Florida and Tampa, Florida.

Why it matters — This acquisition expands Axogen's product offerings with a novel FDA-cleared sutureless nerve repair device, potentially broadening its addressable market in peripheral nerve repair.

Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair

Benzinga · 10 Sept 2026neutral

Axogen Inc. agreed on Thursday to acquire privately held BioCircuit Technologies Inc., a medical device manufacturer, for $200 million in cash. The acquisition is focused on BioCircuit's sutureless nerve repair technology.

Why it matters — The acquisition expands Axogen's portfolio in nerve repair by adding BioCircuit's sutureless technology, which could affect the company's product offerings and competitive position.

2 Medical-Device Stocks Lighting Up the Options Pits

Schaeffers Research · 10 Sept 2026negative

Schaeffers Research reports that Axogen Inc, alongside Cooper Companies, is sharply lower after separate company developments, with options traders responding to the moves.

Why it matters — Axogen watchers would note the sharp decline in the stock following a company development, as it reflects heightened options-market activity around the news.

Axogen, Inc. (AXGN) M&A Call Transcript

Seeking Alpha · 10 Sept 2026neutral

Seeking Alpha published a transcript of a conference call regarding Axogen, Inc.'s (AXGN) merger and acquisition activities. The item is an M&A call transcript for the company.

Why it matters — A transcript of the M&A call gives AXGN watchers direct access to what management discussed regarding the company's merger and acquisition matters.

FAQ

Frequently asked questions about AXGN stock

What is the AXGN stock price forecast for 2026-2027?

The 10 Wall Street analysts covering AxoGen, Inc. have a median 12-month price target of $54, with estimates ranging from $48 to $58. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AXGN stock a buy right now?

Of the 10 analysts covering AxoGen, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AxoGen, Inc. 81 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AXGN?

As at 6 Oct 2026, AxoGen, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will AXGN stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +48.7% from the last close, and Ticker Nerd's factor model ranks AxoGen, Inc. 81 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AXGN stock forecast for 2030?

No analyst covering AxoGen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AXGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $48 to $58 over the next 12 months.

How has AXGN stock performed over the past year?

AxoGen, Inc. returned +111.6% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AxoGen, Inc. do?

Axogen, Inc. is a medical technology company focused on peripheral nerve regeneration and repair.

What is the latest news on AXGN?

The most recent item we track (Zacks Investment Research, 5 Oct 2026): "Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)". AxoGen (AXGN) has declined 22.6% over the past four weeks and is now technically in oversold territory. According to the report, strong agreement among Wall Street analysts in revising earnings estimates higher indicates the stock may be poised for a trend reversal.

Company

About AxoGen, Inc.

Axogen, Inc. is a medical technology company focused on peripheral nerve regeneration and repair. Axogen develops and commercializes surgical solutions used by surgeons and healthcare providers to address nerve injuries caused by trauma, procedures, or disease. Its current product portfolio includes nerve allografts, nerve connectors, nerve protectors, nerve caps, and soft tissue membranes designed to support nerve reconstruction, protection, and functional restoration. The company serves hospitals, surgery centers, military hospitals, and specialists in reconstructive, hand, orthopedic, plastic, and oral and maxillofacial surgery. Axogen plays a specialized role in the medical devices market by offering targeted technologies for peripheral nerve care and by supporting clinical education around surgical treatment of nerve damage. Headquartered in Alachua, Florida, Axogen remains focused on a niche segment of regenerative medicine and surgical reconstruction.

CEO Mr. Michael D. Dale · 622 employees · United States · https://www.axogeninc.com